Endomedix is a development stage MedTech firm that has developed a platform technology (PLEXimine™) based on novel polysaccharide chemistry. PLEXimine forms devices in situ that are structured and dynamic 3D networks. This technology is versatile and can produce an array of different properties for use in the development of a series of separate product categories. Endomedix has been awarded 7 NIH SBIR & 1 NYS grants, and has obtained 9 issued patents based for this technology. The first device using this technology will be PlexiClot™ Absorbable Hemostat for brain & spinal surgeries, an underserved $1.7B niche. PlexiClot addresses major unmet needs in these high value surgeries with a unique technology that cannot be equaled by existing technologies. Additionally, the Company has entered into a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Materiel Development Command (USAMMC) for the development of a treatment system for ocular projectile battlefield trauma using PLEXimine technology. In addition to grants, the Company has raised $3.3 M in private investment.